A clinical trial involving liraglutide, an approved GLP-1 receptor agonist, was listed as recruiting on August 19, 2026. The study, titled "Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment," is registered under identifier NCT07213323. Its phase is listed as not applicable. The trial's current status is recruiting, according to the registry entry dated August 19, 2026. No results or outcome data have been posted for this study at this time. The registration reflects only the trial's design and recruitment status as of the listed date. No efficacy, safety, or comparative claims are included in this update, since none have been reported in the available record. Readers interested in tracking the trial's progress can consult the official registry listing for updates on enrollment, methodology, and eventual results. This brief reflects only the information provided in the trial registration and does not characterize or predict outcomes. For more background on liraglutide, including its approved uses and general profile, readers can consult the compound overview.
Trial Update: Liraglutide-Linked GI Health Study Now Recruiting
See the full liraglutide overview
Source: https://clinicaltrials.gov/study/NCT07213323